Organization
Medical College of Wisconsin
72 clinical trials
58 abstracts
1 poster
Clinical trial
Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway AlterationStatus: Recruiting, Estimated PCD: 2026-06-01
Abstract
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.Org: Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, The Ohio State University James Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, University of Chicago,
Abstract
Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of TRANSCEND CLL 004.Org: Fred Hutchinson Cancer Center, Duke University Health System, Center for Lymphoma, University of Chicago Medical Center, Chicago, IL, Banner MD Anderson Cancer Center,
Abstract
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.Org: City of Hope National Medical Center, Center for International Blood and Marrow Transplant Research, University of North Carolina School of Medicine, Moffitt Cancer Center, Stanford University Hospital,
Abstract
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).Org: University of Chicago, Novartis Institutes for BioMedical Research, Medical College of Wisconsin, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center,
Abstract
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.Org: Vanderbilt University Medical Center, University Hospital of Salamanca, Helen Diller Family Comprehensive Cancer Center, Princess Margaret Cancer Centre, Levine Cancer Institute/Atrium Health,
Abstract
A phase 3 trial of inotuzumab ozogamicin for high-risk B-ALL: Second safety phase results from Children’s Oncology Group AALL1732.Org: Cincinnati Children's Hospital Medical Center, Children's Hospital of Philadelphia, University of Florida Department of Biostatistics, UCSF Benioff Children's Hospital Oakland, Loyola University Medical Center,
Abstract
Biologic indicators of donor socioeconomic disadvantage and recipient mortality following allogeneic hematopoietic cell transplantation.Org: David Geffen School of Medicine at UCLA, University of Colorado-Denver, University of Minnesota, Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research,
Abstract
A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.Org: Mayo Clinic, Northwestern University, UCSF Helen Diller Family Comprehensive Cancer Center, University of Iowa, City of Hope National Medical Center,
Abstract
First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.Org: University College London Cancer Institute, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Medical College of Wisconsin, Peter MacCallum Cancer Centre, Melbourne, Australia, Hematology Clinic,
Abstract
HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results.Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, University of Kansas Medical Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Cleveland Clinic Lerner College of Medicine,
Abstract
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,
Abstract
Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results.Org: Dana-Farber Cancer Institute, Boston Children's Hospital Cancer and Blood Disorders Center, Memorial Sloan Kettering Cancer Center, University of Colorado Denver, Children's Mercy Hospital,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), Department of Biostatistics, University of Pittsburgh School of Public Health, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute, The Ohio State University Comprehensive Cancer Center,
Abstract
ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using FMISO PET and MRI.Org: Massachusetts General Hospital, Brown University School of Medicine-Rhode Island Hospital, University of Washington School of Medicine, Wake Forest University Department of General Internal Medicine, Icahn School of Medcn At Mount Sinai,
Clinical trial
MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal CancerStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Fosamprenavir/Lexiva for Laryngopharyngeal Reflux (LPR)Status: Not yet recruiting, Estimated PCD: 2025-10-15
Clinical trial
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease. (BMTCTN1507)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Reducing the Risk of Chronic Hypertension and Improving Vascular Function FollowingStatus: Not yet recruiting, Estimated PCD: 2029-06-30
Clinical trial
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical TransplantationStatus: Recruiting, Estimated PCD: 2025-11-16
Clinical trial
A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML)Status: Terminated, Estimated PCD: 2021-12-12
Abstract
Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell–associated neurotoxicity syndrome (ICANS).Org: The Ohio State University College of Medicine, The Ohio State University - Division of Hematology, Medical College of Wisconsin, Division of Hematology, The Ohio State University,
Abstract
Neoadjuvant aromatase inhibitor therapy for ER+ breast cancer: The NAOMI trial.Org: Dartmouth-Hitchcock Medical Center, Dartmouth College Geisel School of Medicine, Medical College of Wisconsin,
Abstract
Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Center for International Blood and Marrow Transplant Research,
Abstract
MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.Org: Sarah Cannon Research Institute/Tennessee Oncology, Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh, Medical College of Wisconsin, Next Oncology Virginia and Virginia Cancer Specialists, Medical University of South Carolina Hollings Cancer Center,
Clinical trial
A Phase 1 Clinical Trial of Oral Gallium Maltolate for the Treatment of Relapsed and Refractory GlioblastomaStatus: Recruiting, Estimated PCD: 2025-12-01
Abstract
Sexual health outcomes in sexual minority vs. heterosexual men after prostate radiotherapy.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, Medical College of Wisconsin, Division of Infectious Diseases,
Clinical trial
Phase I Study Evaluating Safety and Feasibility of Hematopoietic Stem Cell Gene Transfer That Targets Factor VIII Delivery From Platelets for Patients With Hemophilia AStatus: Recruiting, Estimated PCD: 2025-03-31
Abstract
Transcriptomic and epigenetic characterization of mucinous adenocarcinoma of the cervix.Org: Medical College of Wisconsin, Rutgers New Jersey Medical School,
Clinical trial
Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron DamageStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)Status: Recruiting, Estimated PCD: 2027-10-01
Clinical trial
Phase I Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-armed Anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2028-12-01
Clinical trial
PK Analysis of Antitumor B in Patients With Oral CancerStatus: Active (not recruiting), Estimated PCD: 2022-02-15
Clinical trial
A Single-blind Randomized Placebo Controlled Trial of Lidocaine Patches for Opioid Reduction in Geriatric Rib Fracture Patients Admitted to the HospitalStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Use of β-hydroxy-β-methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men With Prostate Cancer Started on Androgen Deprivation TherapyStatus: Completed, Estimated PCD: 2018-07-01
Clinical trial
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian CancerStatus: Completed, Estimated PCD: 2022-05-01
Clinical trial
Ketamine Infusion for Pain Control in Severe Traumatic Injury: A Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 InfectionStatus: Completed, Estimated PCD: 2021-02-10
Clinical trial
Phase I Study of BCMA-TGF-BETA Insensitive Armored CAR T Cells in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Intensive Postpartum Antihypertensive Treatment to Improve Women's Cardiovascular Health (IPAT Study)Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Sex-specific Effects of Continuous Estrogen on Human in Vivo Microvascular FunctionStatus: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain MetastasesStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Utility of Exosomal microRNAs to Predict Response to Androgen Deprivation Therapy in Prostate Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2021-05-11
Clinical trial
Oral Penicillin Challenge in the Pediatric Emergency DepartmentStatus: Completed, Estimated PCD: 2020-12-04
Clinical trial
Inhibition of Oral Tumorigenesis by Antitumor BStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
PK Analysis of Antitumor B KAC in Patients With Oral CancerStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients With Relapsed and/or Refractory B Cell MalignanciesStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Role of Autophagy in Type 2 Diabetes Microvascular DysfunctionStatus: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
Phase II Study of PD-1 Inhibition With Cemiplimab in Locally Advanced Hormone Receptor (HR) Positive HER2 Negative or Triple-Negative Breast Cancer Patients Undergoing Standard Neoadjuvant ChemotherapyStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion PatientsStatus: Completed, Estimated PCD: 2022-01-01
Clinical trial
A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)Status: Completed, Estimated PCD: 2022-09-19
Clinical trial
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma PatientsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Transdermal Buprenorphine for the Treatment of Radiation-Induced Mucositis Pain in Head and Neck Cancer Patients: A Pilot StudyStatus: Active (not recruiting), Estimated PCD: 2024-04-04
Clinical trial
A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) After BCMA-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration SamplesStatus: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)Status: Not yet recruiting, Estimated PCD: 2027-06-15
Clinical trial
A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN 1503)Status: Completed, Estimated PCD: 2023-05-02
Clinical trial
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-metastatic Pancreatic CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-13
Clinical trial
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial CarcinomaStatus: Completed, Estimated PCD: 2023-03-30
Clinical trial
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Gestational Diabetes and Pharmacotherapy (GAP) - A Randomized Controlled Trial Investigating Timing of Pharmacotherapy Initiation for Patients With Gestational DiabetesStatus: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
Prospective Analysis of Immunogenicity of the Nonavalent Human Papillomavirus Vaccination (GARDASIL 9) in Patients Pre and Post Solid Organ TransplantStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the PancreasStatus: Completed, Estimated PCD: 2018-06-01
Clinical trial
Phase 1/1b Study of Redirected Autologous T Cells Engineered to Contain an Anti CD19 and Anti CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory CD19 or CD20 Positive B Cell MalignanciesStatus: Completed, Estimated PCD: 2019-10-01
Clinical trial
Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
Combination Post-transplant Consolidation Therapy With Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients With Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)Status: Recruiting, Estimated PCD: 2026-09-15
Clinical trial
Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic CancerStatus: Completed, Estimated PCD: 2018-09-25
Clinical trial
A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine ResistanceStatus: Active (not recruiting), Estimated PCD: 2020-02-04
Clinical trial
An Open-label, Navigational Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor PrognosesStatus: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase I Study of Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaStatus: Completed, Estimated PCD: 2024-05-22
Clinical trial
A Phase II Study Analyzing Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma (PRORADGLIO Study)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti-CD19 and Anti-CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed/ Refractory CD19 or CD20 B-cell Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Network-Level Mechanisms for Preclinical Alzheimer's Disease DevelopmentStatus: Completed, Estimated PCD: 2021-03-31
Clinical trial
Recognition of Circulating Tumor DNA in Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase II Trial of De-escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCTStatus: Recruiting, Estimated PCD: 2025-12-15
Clinical trial
PROACTIVE: Prevention of Acute and Chronic GVHD Using TocIlizumab in Combination With Standard GVHD Prophylaxis After allogEneic TransplantationStatus: Completed, Estimated PCD: 2022-03-02
Clinical trial
A Phase I Study of Venetoclax to Augment Epigenetic Modification and Chemotherapy in Pediatric and Young Adult Patients With Relapsed and Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
A Comparison of the Analgesic Effects of Pectointercostal Fascial Plane Block (PIFB) Alone Versus PIFB With Rectus Sheath Block (RSB) in Cardiac Surgery: a Prospective, Randomized Controlled Trial.Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I Trial of MR-Guided Dose-Escalated Hypofractionated Adaptive Radiation Therapy and Immunotherapy in Primary Metastatic or Very Locally Advanced Patients With Head and Neck CancerStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight InfantsStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase I Study of LV20.19 CAR T-cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)Status: Completed, Estimated PCD: 2021-04-06
Clinical trial
A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid MalignanciesStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
Interstitial Cystitis: Examination of the Central Autonomic NetworkStatus: Completed, Estimated PCD: 2022-03-16
Clinical trial
Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2023-11-30
Clinical trial
A Pilot Study to Evaluate 18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing ChemotherapyStatus: Terminated, Estimated PCD: 2023-05-08
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The vulvar cancers.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, Il-Yang Pharmaceuticals, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle Gummy Company,
Abstract
Long-term safety with ≥12 months of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies.Org: UCI Health, Medical College of Wisconsin, Maria Sklodowska-Curie National Research Institute of Oncology, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Linear Clinical Research and Sir Charles Gairdner Hospital,
Abstract
Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).Org: Medical College of Wisconsin, Milwaukee, Froedtert & Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, University of Arkansas Medical Sciences,
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: Medical College of Wisconsin, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, University Hospitals Seidman Cancer Center,
Abstract
A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial).Org: Sarah Cannon Research Institute/Tennessee Oncology, Department of Hematology, University of California San Francisco, Icahn School of Medicine, Mount Sinai, Onc/Hem Care Inc, Center for Discovery and Innovation, Hackensack Meridian Health,
Abstract
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.Org: Fred Hutchinson Cancer Research Center, Boston University Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Medical College of Wisconsin,
Abstract
Impact of state policies on telehealth use among the privately insured with newly diagnosed cancer.Org: MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Medical College of Wisconsin,
Abstract
ExoLuminate: An observational registry study for detection of pancreatic adenocarcinoma (PDAC) in high-risk or clinically suspicious patients.Org: Biological Dynamics, Inc., Medical College of Wisconsin, WIN Consortium,
Abstract
Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center,
Abstract
ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI).Org: Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Correlation of cardiovascular disease with racial disparities in endometrial cancer outcomes.Org: Medical College of Wisconsin, Froedtert and the Medical College of Wisconsin Workforce Health, Milwaukee, WI,
Abstract
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).Org: H. Lee Moffitt Cancer Center and Research Institute, University of Miami Sylvester Cancer Center, Ronald Reagan UCLA Medical Center, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ, Colorado Blood Cancer Institute and Sarah Cannon Research Institute,
Abstract
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,
Abstract
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.Org: Pangea Biomed, National Cancer Institute, Vilnius, Lithuania, Cancer Data Science Laboratory (CDSL), National Institutes of Health All of Us Research Program, Women’s Malignancies Branch,
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, UC San Diego Moores Cancer Center, University of Kansas Medical Center, Department of Biostatistics & Data Science, Loma Linda University Department of Radiation Technology,
Abstract
A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.Org: Memorial Sloan Kettering Cancer Center, University of Kansas Medical Center Department of Internal Medicine, NSABP/NRG Oncology and Wake Forest University Baptist Medical Center, Gettysburg Cancer Center, University of Arizona Cancer Center,
Abstract
Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).Org: Medical College of Wisconsin, Froedtert & Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, University of Wisconsin Madison School of Medicine and Public Health, Division of Hematology & Oncology,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), NRG Oncology SDMC, The University of Pittsburgh, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute,
Abstract
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.Org: Veracyte, Inc., South Australian Immunogenomics Cancer Institute, Institute of Cancer Research, Medical College of Wisconsin, Cedars-Sinai Medical Center,
Abstract
Association between locoregional failure and NFE2L2/KEAP1/CUL3 pathway mutations in NRG/RTOG 9512: A randomized trial of hyperfractionation vs. conventional fractionation in T2N0 glottic squamous cell carcinoma (SCC).Org: NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Washington University School of Medicine in St. Louis, University of Pittsburgh, Pittsburgh, PA, Loyola University Medical Center, Juravinski Cancer Centre at Hamilton Health Sciences,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).Org: Massachusetts General Hospital, Incyte, Medical College of Wisconsin, Oregon Health & Science University, Washington University School of Medicine in St. Louis,
Abstract
A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).Org: Zentalis Pharmaceuticals, Memorial Sloan Kettering Cancer Center, Medical College of Wisconsin, The James Cancer Hospital and Solove Research Institute, University of Texas M.D. Anderson Cancer Center,
Abstract
Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer.Org: NEXT Oncology - Virginia Cancer Specialists, The Sarah Cannon Research Institute, Department of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, UPMC Hillman Cancer Center, Medical College of Wisconsin,
Abstract
Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).Org: MGH Cancer Center, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Medical College of Wisconsin, Norris Comprehensive Cancer Center,
Abstract
Oncologists’ receipt of pharmaceutical industry payments and use of non-recommended and low-value cancer care services.Org: Memorial Sloan Kettering Cancer Center, Vanderbilt University School of Medicine, DELFI Diagnostics, Medical College of Wisconsin,
Abstract
Sequential salvage chemotherapy and lintuzumab-Ac225 results in deep responses and prolonged survival in adverse risk relapsed/refractory AML and in AML patients that received prior venetoclax therapy.Org: Medical College of Wisconsin, Actinium Pharmaceuticals,
Abstract
Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.Org: Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, University of Colorado Denver Anschutz Medical Center, Aurora, CO,
Abstract
Correlation between biomarkers and treatment outcomes in diverse cancers: A meta-analysis of phase I and II immunotherapy clinical trials.Org: St Lukes Clinic, University of Texas MD Anderson Cancer Center, University of Texas at Austin, Medical College of Wisconsin, WIN Consortium,
Abstract
National trends in neoadjuvant chemotherapy utilization for cT1-2 N0 triple negative breast cancer: Did the CREATE-X trial impact treatment patterns?Org: Medical College of Wisconsin, University of Wisconsin-Milwaukee, University of Texas MD Anderson Cancer Center,
Abstract
Impact of centralization of initial breast cancer care on time to surgery.Org: Medical College of Wisconsin, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York State Cancer Registry,
Abstract
Characterizing imposter syndrome among oncologists on social media.Org: Valley Health System, Paramus, NJ, Medical College of Wisconsin, Milwaukee, WI, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.Org: National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Cleveland Clinic Taussig Cancer Instititute, Medical College of Wisconsin, NYU Langone Laura and Isaac Perlmutter Cancer Center,
Abstract
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.Org: Cincinnati Children's Hospital Medical Center, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, Division of Pediatric Hematology-Oncology, Department of Pediatrics, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, QC, Canada, Oncology and Bone Marrow Transplant, School of Medicine & Public Health,
Abstract
Community resilience and its impact on chemotherapy availability: An ecological analysis.Org: Cancer Care & Research Center, Marshfield Clinic Research Institute, Institute for Health and Equity, Medical College of Wisconsin, Wisconsin NCORP,
Abstract
Overall survival (OS) and pathologic response rate from a phase II clinical trial of neoadjuvant GVAX pancreas vaccine (with cyclophosphamide) in combination with nivolumab and stereotactic body radiation therapy (SBRT) followed by definitive resection for patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC).Org: Abramson Cancer Center at the University of Pennsylvania, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Medical College of Wisconsin, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Cedars-Sinai Medical Center,
Abstract
Outcome differences by sex in oncology clinical trials.Org: Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Medical College of Wisconsin, WIN Consortium,
Abstract
Real-world experience with liposomal doxorubicin in metastatic and locally advanced sarcoma.Org: Medical College of Wisconsin, Froedtert Hospital Cancer Center,